Management of prolactinoma during pregnancy and postpartum
Prolactinoma is classified as microprolactinoma when it measures <10 mm and macroprolactinoma when it measures ≥10 mm. Prolactinoma is an important cause of amenorrhea and infertility in premenopausal female. With early diagnosis and treatment with dopamine agonist, many patients have restoration...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer – Medknow Publications
2015-01-01
|
| Series: | Journal of Integrated Health Sciences |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/2347-6486.238517 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850150610880430080 |
|---|---|
| author | Om J Lakhani Rishma Lakhani M Desai M Tripathi |
| author_facet | Om J Lakhani Rishma Lakhani M Desai M Tripathi |
| author_sort | Om J Lakhani |
| collection | DOAJ |
| description | Prolactinoma is classified as microprolactinoma when it measures <10 mm and macroprolactinoma when it measures ≥10 mm. Prolactinoma is an important cause of amenorrhea and infertility in premenopausal female. With early diagnosis and treatment with dopamine agonist, many patients have restoration of fertility within few months of treatment. In presence of estrogenic environment of pregnancy there is a tendency for prolactinoma to increase in size during pregnancy. This may be associated with visual field compromise and rarely pituitary apoplexy. This review discusses some key points in management of prolactinoma during pregnancy and postpartum.
In case of microprolactinoma, the risk of complications are low hence it is recommended to keep a close follow up of patient without any need for intervention. In case of macroprolactinoma it is recommended to use barrier contraception to prevent pregnancy for at least 6-12 months after detection and starting treatment to allow proper shrinkage of the tumor with dopamine agonist. Once pregnancy is confirmed -In those with low risk features, dopamine agonist is stopped and a close follow up is advised. In those with high risk features, it is recommended to continue the dopamine agonist therapy with a close follow up. Postpartum period generally doesn't pose much threat to prolactinoma and treatment may be discontinued if patient wishes to breast feed her infant. |
| format | Article |
| id | doaj-art-83c769901a9d4cec8b7bdc6cfd5f9ea1 |
| institution | OA Journals |
| issn | 2347-6486 2347-6494 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wolters Kluwer – Medknow Publications |
| record_format | Article |
| series | Journal of Integrated Health Sciences |
| spelling | doaj-art-83c769901a9d4cec8b7bdc6cfd5f9ea12025-08-20T02:26:31ZengWolters Kluwer – Medknow PublicationsJournal of Integrated Health Sciences2347-64862347-64942015-01-01313710.4103/2347-6486.238517Management of prolactinoma during pregnancy and postpartumOm J LakhaniRishma LakhaniM DesaiM TripathiProlactinoma is classified as microprolactinoma when it measures <10 mm and macroprolactinoma when it measures ≥10 mm. Prolactinoma is an important cause of amenorrhea and infertility in premenopausal female. With early diagnosis and treatment with dopamine agonist, many patients have restoration of fertility within few months of treatment. In presence of estrogenic environment of pregnancy there is a tendency for prolactinoma to increase in size during pregnancy. This may be associated with visual field compromise and rarely pituitary apoplexy. This review discusses some key points in management of prolactinoma during pregnancy and postpartum. In case of microprolactinoma, the risk of complications are low hence it is recommended to keep a close follow up of patient without any need for intervention. In case of macroprolactinoma it is recommended to use barrier contraception to prevent pregnancy for at least 6-12 months after detection and starting treatment to allow proper shrinkage of the tumor with dopamine agonist. Once pregnancy is confirmed -In those with low risk features, dopamine agonist is stopped and a close follow up is advised. In those with high risk features, it is recommended to continue the dopamine agonist therapy with a close follow up. Postpartum period generally doesn't pose much threat to prolactinoma and treatment may be discontinued if patient wishes to breast feed her infant.https://journals.lww.com/10.4103/2347-6486.238517hyperprolactinemia and pregnancyprolactinoma and pregnancyprolactinoma and postpartum |
| spellingShingle | Om J Lakhani Rishma Lakhani M Desai M Tripathi Management of prolactinoma during pregnancy and postpartum Journal of Integrated Health Sciences hyperprolactinemia and pregnancy prolactinoma and pregnancy prolactinoma and postpartum |
| title | Management of prolactinoma during pregnancy and postpartum |
| title_full | Management of prolactinoma during pregnancy and postpartum |
| title_fullStr | Management of prolactinoma during pregnancy and postpartum |
| title_full_unstemmed | Management of prolactinoma during pregnancy and postpartum |
| title_short | Management of prolactinoma during pregnancy and postpartum |
| title_sort | management of prolactinoma during pregnancy and postpartum |
| topic | hyperprolactinemia and pregnancy prolactinoma and pregnancy prolactinoma and postpartum |
| url | https://journals.lww.com/10.4103/2347-6486.238517 |
| work_keys_str_mv | AT omjlakhani managementofprolactinomaduringpregnancyandpostpartum AT rishmalakhani managementofprolactinomaduringpregnancyandpostpartum AT mdesai managementofprolactinomaduringpregnancyandpostpartum AT mtripathi managementofprolactinomaduringpregnancyandpostpartum |